NCT01908205View on ClinicalTrials.gov

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Intranasal Oxytocin

DRUG

Placebo

Trial Locations (2)

55455

University of Minnesota, Minneapolis

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT01908205 - Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD) | Biotech Hunter | Biotech Hunter